507 related articles for article (PubMed ID: 22632451)
1. Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan.
Igarashi A; Kuwabara H; Fahrbach K; Schenkel B
J Dermatolog Treat; 2013 Oct; 24(5):351-5. PubMed ID: 22632451
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
4. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.
Imafuku S; Nakano A; Dakeshita H; Li J; Betts KA; Guerin A
J Dermatolog Treat; 2018 Feb; 29(1):24-31. PubMed ID: 28608740
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a meta-analysis and cost-efficacy analysis using the intention-to-treat principle.
Chi CC; Wang SH
Biomed Res Int; 2014; 2014():862851. PubMed ID: 24605338
[TBL] [Abstract][Full Text] [Related]
6. Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.
Wang SH; Chi CC; Hu S
Int J Dermatol; 2014 Sep; 53(9):1151-6. PubMed ID: 24738910
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
Wu JJ; Feldman SR; Rastogi S; Menges B; Lingohr-Smith M; Lin J
J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
[TBL] [Abstract][Full Text] [Related]
8. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
9. A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis.
Núñez M; Huete T; de la Cueva P; Sacristán JA; Hartz S; Dilla T
Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):546-553. PubMed ID: 30851873
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response.
Signorovitch JE; Betts KA; Yan YS; LeReun C; Sundaram M; Wu EQ; Mulani P
Br J Dermatol; 2015 Feb; 172(2):504-12. PubMed ID: 25288183
[TBL] [Abstract][Full Text] [Related]
12. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
Ferrándiz C; García A; Blasco AJ; Lázaro P
J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
[TBL] [Abstract][Full Text] [Related]
13. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.
Sruamsiri R; Iwasaki K; Tang W; Mahlich J
BMC Dermatol; 2018 Jul; 18(1):5. PubMed ID: 29996929
[TBL] [Abstract][Full Text] [Related]
14. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
[TBL] [Abstract][Full Text] [Related]
15. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
[TBL] [Abstract][Full Text] [Related]
16. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
[TBL] [Abstract][Full Text] [Related]
17. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of systemic therapies for moderate to severe psoriasis.
Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
[TBL] [Abstract][Full Text] [Related]
19. Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.
Ueno F; Doi M; Kawai Y; Ukawa N; Cammarota J; Betts KA
J Med Econ; 2020 Jan; 23(1):80-85. PubMed ID: 31294641
[No Abstract] [Full Text] [Related]
20. Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service.
Puig L; Notario J; Jiménez-Morales A; Moreno-Ramírez D; López-Ferrer A; Gozalbo I; Prades M; Lizán L; Blanch C
J Dermatolog Treat; 2017 Nov; 28(7):623-630. PubMed ID: 28784002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]